Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Infinity Pharmaceuticals is a biotechnology business based in the US. Infinity Pharmaceuticals shares (INFI) are listed on the NASDAQ and all prices are listed in US Dollars.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $0.64 |
|---|---|
| 52-week range | $0.44 - $1.76 |
| 50-day moving average | $0.58 |
| 200-day moving average | $0.87 |
| Wall St. target price | $5.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.52 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.6352 from 2023-02-02
| 1 week (2023-01-27) | -0.75% |
|---|---|
| 1 month (2023-01-03) | 11.44% |
| 3 months (2022-11-03) | -47.93% |
| 6 months (2022-08-03) | -10.03% |
| 1 year (2022-01-30) | N/A |
|---|---|
| 2 years (2021-02-03) | -82.83% |
| 3 years (2020-02-03) | 1.29 |
| 5 years (2018-02-02) | 2.01 |
| Revenue TTM | $2.5 million |
|---|---|
| Gross profit TTM | $-30,909,000 |
| Return on assets TTM | -40.02% |
| Return on equity TTM | -439.96% |
| Profit margin | 0% |
| Book value | $-0.12 |
| Market capitalisation | $56.8 million |
TTM: trailing 12 months
We're not expecting Infinity Pharmaceuticals to pay a dividend over the next 12 months.
Infinity Pharmaceuticals's shares were split on a 1:4 basis on 12 September 2006. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Infinity Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Infinity Pharmaceuticals shares which in turn could have impacted Infinity Pharmaceuticals's share price.
Over the last 12 months, Infinity Pharmaceuticals's shares have ranged in value from as little as $0.44 up to $1.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Infinity Pharmaceuticals's is 1.2347. This would suggest that Infinity Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Infinity Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.